Thus, the results from our previous study together with the results presented in Table S1 suggest that endocan is a better biomarker than the p14 endocan fragment for characterization of patient heterogeneity also for the majority of acute leukemia patients not requiring transfer to intensive care units for life-supportive therapy. Here, ESM1 is linked to acute leukemia.